Compare RAND & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RAND | IXHL |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 49.1M |
| IPO Year | N/A | N/A |
| Metric | RAND | IXHL |
|---|---|---|
| Price | $15.02 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.2K | ★ 23.8M |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | ★ 11.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,327,287.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.25 | $0.08 |
| 52 Week High | $31.89 | $2.25 |
| Indicator | RAND | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 63.36 | 59.02 |
| Support Level | $13.95 | $0.35 |
| Resistance Level | $15.49 | $0.50 |
| Average True Range (ATR) | 0.39 | 0.03 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 78.79 | 68.63 |
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.